Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.

Journal: Molecular Cell

Published: 2019-12-10

DOI: 10.1016/j.molcel.2019.11.009

Affiliations: 15

Authors: 32

Go to article
Institutions Share
Immunology, Microenvironment and Metastasis Program, The Wistar Institute, United States of America (USA) 0.43
Abramson Cancer Center, Penn, United States of America (USA) 0.22
Molecular and Cellular Oncogenesis Program, The Wistar Institute, United States of America (USA) 0.14
University of the Sciences in Philadelphia (USciences), United States of America (USA) 0.05
Bioinformatics Facility, The Wistar Institute, United States of America (USA) 0.03
Fox Chase Cancer Center (FCCC), Temple University, United States of America (USA) 0.03
Department of Biochemistry and Biophysics, Penn, United States of America (USA) 0.02
First Affiliated Hospital, ZJU, China 0.02
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, ZJU, China 0.02
Lankenau Institute for Medical Research (LIMR), United States of America (USA) 0.02
Department of Surgery, Penn, United States of America (USA) 0.01
University of Pennsylvania Health System (UPHS), United States of America (USA) 0.01
Department of Biochemistry and Molecular Biology, JHU, United States of America (USA) 0.01
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER